



(51) International Patent Classification:

A61K 39/00 (2006.01) *C07K 16/30* (2006.01)
A61K 39/395 (2006.01) *G01N 33/574* (2006.01)
C07K 16/28 (2006.01)

(21) International Application Number:

PCT/US2018/018513

(22) International Filing Date:

16 February 2018 (16.02.2018)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/459,700 16 February 2017 (16.02.2017) US

(71) Applicant: MEDIMMUNE, LLC [US/US]; One Medimmune Way, Gaithersburg, MD 20878 (US).

(72) Inventors: **KURLAND, John**; c/o Medimmune, LLC, One Medimmune Way, Gaithersburg, MD 20878 (US).
BLAKE-HASKINS, John, Andrew; c/o Medimmune, LLC, One Medimmune Way, Gaithersburg, MD 20878 (US).
ZAJAC, Magdalena; c/o Medimmune Limited, Milstein Building, Granta Park, Cambridge CB21 6GH (GB).
REBELATTO, Marlon; c/o Medimmune, LLC, One Medimmune Way, Gaithersburg, MD 20878 (US).
GUPTA,


Ashok; c/o Medimmune, LLC, One Medimmune Way, Gaithersburg, MD 20878 (US). **HO, Tony**; c/o Medimmune, LLC, One Medimmune Way, Gaithersburg, MD 20878 (US). **WALKER, Jill**; c/o Medimmune, LLC, Milstein Building, Granta Park, Cambridge CB21 6GH (GB). **JIN, Xiaoping**; c/o Medimmune, LLC, One Medimmune Way, Gaithersburg, MD 20878 (US). **MORRIS, Shannon**; c/o Medimmune, LLC, One Medimmune Way, Gaithersburg, MD 20878 (US). **IANNONE, Robert**; c/o Medimmune, LLC, One Medimmune Way, Gaithersburg, MD 20878 (US). **SHI, Li**; c/o Medimmune, LLC, One Medimmune Way, Gaithersburg, MD 20878 (US). **DAR, Mohammed**; c/o Medimmune, LLC, One Medimmune Way, Gaithersburg, MD 20878 (US). **BEN, Yong**; c/o Medimmune, LLC, One Medimmune Way, Gaithersburg, MD 20878 (US).

(74) Agent: **MENSAH, Kwame, N.** et al.; c/o Medimmune, LLC, One Medimmune Way, Gaithersburg, MD 20878 (US).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,

(54) Title: ANTI-PD-L1 ANTIBODY TREATMENT OF BLADDER CANCER

FIGURE 1



(57) Abstract: Provided are methods of treating bladder cancer (e.g., urothelial carcinoma, UC) in a subject having bladder cancer, e.g., UC, with an effective dose regimen of an anti-PD-L1 antibody, e.g., durvalumab, or an antigen binding fragment thereof. Also provided are methods in which an anti-PD-L1 antibody is used in combination with another immunotherapeutic agent, e.g., tremelimumab to treat a bladder cancer, e.g., UC, in a subject having bladder cancer. In some cases, the subject undergoing treatment is identified as having a bladder cancer or tumor that is PD-L1-low/neg, or PD-L1-high. Methods are also provided in which anti-PD-L1 antibody treatment of bladder cancer is used following a standard of care or first-line therapy in subjects who have progressed following such therapies or who have relapsed after a prior treatment regimen.

KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (*Art. 21(3)*)
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (*Rule 48.2(h)*)